Communiqués SciSparc Ltd.

Actions

SPRC

IL0010951403

Produits pharmaceutiques

Marché Fermé - Nasdaq 21:21:19 14/08/2026			Varia. 5j.	Varia. 1 janv.
6,500 ^USD	-2,84%		-6,20%	-46,90%

05/08	SciSparc Ltd. lance un essai clinique de phase IIb au Yale Child Study Center pour le SCI-110 dans le traitement du syndrome de la Tourette	CI
29/07	SciSparc Ltd. annonce la création d'un conseil consultatif scientifique	CI

Communiqués

12/08	SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination	GL
05/08	SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome	GL
31/07	SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics	GL
30/07	SciSparc, Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company	AQ
29/07	SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company	GL
27/07	SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity	GL
15/07	SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome	GL
05/06	SciSparc, Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum	AQ
04/06	SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum	GL
28/05	SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum	GL
16/03	SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy	GL
12/03	SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease	GL
11/03	SciSparc, Subsidiary NeuroThera Labs Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails	AQ
10/03	SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails	GL
02/03	SciSparc Announces 1-for-9 Reverse Share Split	GL
02/02	SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA	GL
26/01	SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization	GL
13/01	SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity	GL
12/01	SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance	GL
12/01	SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance	AQ
30/12	SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects	GL
02/12	SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company	GL
01/12	SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio	GL
26/11	SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems	GL
21/11	SciSparc, Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression	AQ